Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Zest Health, the first value-based virtual care company focused on treating patients with inflammatory skin diseases, today announced $13 million in seed funding. Zest Health’s platform provides ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over the trial’s batoclimab. Wednesday, Immunovant, Inc. (NASDAQ ...

Roivant’s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

He said the company reported notable data for its first-generation FcRn inhibitor, batoclimab, that treats myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. This supports ...

The company announced this month that it confirmed the efficacy of batoclimab in phase 3 clinical trials for myasthenia gravis and phase 2b clinical trials for chronic inflammatory demyelinating ...